Aktis Oncology, Inc. (AKTS) vs Vor Biopharma Inc. (VOR)

A side-by-side comparison of Aktis Oncology, Inc. and Vor Biopharma Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Aktis Oncology, Inc. logo
AKTS
Aktis Oncology, Inc.
$954M
$17.86HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Vor Biopharma Inc. logo
VOR
Vor Biopharma Inc.
$992M
$18.31HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — AKTS vs VOR

growth of $100 · dividends reinvested · last 1y
AKTS -17.3% (-17.3%/yr)VOR +45.4% (+45.4%/yr)VOR compounded faster over this window
100150200Start $100$83$145
AKTS VOR

AKTS vs VOR: by the numbers

  • •VOR is the larger company ($992M vs $954M market cap).
  • •Both run net losses; VOR's is the smaller (0.00% vs -727.04% net margin).

Metrics side by side

Valuation

MetricAKTSVOR
P/S ratio94.81N/A
P/B ratio1.97N/A

Profitability

MetricAKTSVOR
Gross margin100.00%0.00%
Operating margin-1149.52%0.00%
Net margin-727.04%0.00%
ROE-15.09%N/A
ROIC-16.54%-32.24%

Growth (annualized)

MetricAKTSVOR
Total return CAGR (5Y)N/A-42.54%

Go deeper

Full AKTS analysisFull VOR analysisInteractive comparison tool

Dig into the metrics

Aktis Oncology ROEVor Biopharma ROEAktis Oncology operating marginVor Biopharma operating marginAktis Oncology revenue growthVor Biopharma revenue growthAktis Oncology free cash flowVor Biopharma free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.